Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.
Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, de Las Peñas R, Gil-Gil M, Sepúlveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C. Estival A, et al. Among authors: velarde jm. Sci Rep. 2019 Jul 31;9(1):11125. doi: 10.1038/s41598-019-47642-2. Sci Rep. 2019. PMID: 31366977 Free PMC article. Clinical Trial.
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Balaña C, et al. Among authors: velarde jm. Clin Transl Oncol. 2018 Dec;20(12):1529-1537. doi: 10.1007/s12094-018-1883-7. Epub 2018 May 8. Clin Transl Oncol. 2018. PMID: 29737461
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Prognostic value of stem cell markers in glioblastoma.
Alameda F, Velarde JM, Carrato C, Vidal N, Arumí M, Naranjo D, Martinez-Garcia M, Ribalta T, Balañá C. Alameda F, et al. Among authors: velarde jm. Biomarkers. 2019 Nov;24(7):677-683. doi: 10.1080/1354750X.2019.1652345. Epub 2019 Sep 8. Biomarkers. 2019. PMID: 31496301
Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.
Capellades J, Puig J, Domenech S, Pujol T, Oleaga L, Camins A, Majós C, Diaz R, de Quintana C, Teixidor P, Conesa G, Plans G, Gonzalez J, García-Balañà N, Velarde JM, Balaña C. Capellades J, et al. Among authors: velarde jm. J Neurooncol. 2018 Apr;137(2):367-377. doi: 10.1007/s11060-017-2726-z. Epub 2017 Dec 28. J Neurooncol. 2018. PMID: 29285591
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.
Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB. Panciroli C, et al. Among authors: velarde jm. Clin Transl Oncol. 2020 Mar;22(3):411-419. doi: 10.1007/s12094-019-02143-6. Epub 2019 May 29. Clin Transl Oncol. 2020. PMID: 31144211
Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients.
Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, España S, Cucurull M, Montprade E, Pardo JC, Carballo D, Velarde JM, Margeli M. Hardy-Werbin M, et al. Among authors: velarde jm. Sci Rep. 2019 Sep 4;9(1):12760. doi: 10.1038/s41598-019-49251-5. Sci Rep. 2019. PMID: 31484985 Free PMC article. Clinical Trial.
Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Morán T, et al. Among authors: velarde jm. Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2. Oncotarget. 2019. PMID: 31069018 Free PMC article.
14 results